Arcturus Therapeutics Holdings Inc.
ARCT
$8.25
-$0.39-4.46%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 54.71M | 82.03M | 97.60M | 122.12M | 143.68M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 54.71M | 82.03M | 97.60M | 122.12M | 143.68M |
| Cost of Revenue | 98.85M | 112.21M | 131.52M | 147.39M | 176.48M |
| Gross Profit | -44.14M | -30.18M | -33.92M | -25.26M | -32.80M |
| SG&A Expenses | 44.23M | 46.08M | 44.43M | 47.31M | 49.29M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 143.08M | 158.29M | 175.95M | 194.70M | 225.76M |
| Operating Income | -88.37M | -76.26M | -78.35M | -72.57M | -82.08M |
| Income Before Tax | -78.67M | -65.78M | -66.71M | -60.38M | -68.57M |
| Income Tax Expenses | 0.00 | 0.00 | 0.00 | -217.00K | -371.00K |
| Earnings from Continuing Operations | -78.67 | -65.78 | -66.71 | -60.16 | -68.20 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -78.67M | -65.78M | -66.71M | -60.16M | -68.20M |
| EBIT | -88.37M | -76.26M | -78.35M | -72.57M | -82.08M |
| EBITDA | -85.48M | -73.24M | -75.19M | -69.26M | -78.64M |
| EPS Basic | -2.82 | -2.39 | -2.46 | -2.22 | -2.52 |
| Normalized Basic EPS | -1.76 | -1.49 | -1.54 | -1.40 | -1.59 |
| EPS Diluted | -2.82 | -2.39 | -2.46 | -2.22 | -2.52 |
| Normalized Diluted EPS | -1.76 | -1.49 | -1.54 | -1.40 | -1.59 |
| Average Basic Shares Outstanding | 110.85M | 109.54M | 108.42M | 108.30M | 108.14M |
| Average Diluted Shares Outstanding | 110.85M | 109.54M | 108.42M | 108.30M | 108.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |